RWS speeds up your go-to-trial strategy: How bulk-ordering paper COA translations in advance benefits your studies

Dan Herron Dan Herron Vice President of Digital Health at RWS 03 Oct 2025 2 minutes read 2 minutes read

The need for speed

With tight submission deadlines, rapidly changing site priorities, and ever-evolving regulations, pharmaceutical sponsors are always looking for ways to speed up the translation process for their studies’ clinical outcomes assessments.
 
At RWS, we know how vital it is to get clear, accurate COA translations in front of patients as quickly as possible.
 
Recently, we've partnered with several of our large pharmaceutical sponsor clients on a plan to proactively translate paper COA translations as far ahead of First Patient Visit dates as possible. This way, they’re ready when it comes time to start eCOA work or to launch their paper-only trials, saving both time and money.

How it works

Most clinical trials, no matter the therapeutic area, include some common, public-domain COAs in their protocols. These are ideal candidates for early paper translation, since no license agreements or developer reviews are required. Licensed scales can also be translated in advance, provided the copyright holder agrees to a license agreement that covers the full period from translation request to FPFV date.

To try to get as many translations ordered in advance as possible, pharmaceutical sponsors can assess their COA translation needs for their upcoming pipeline, be it for a therapeutic area, a specific drug or a series of trials. Sponsors often have several trials coming up in the next year that all use similar COAs, and/or a large country footprint where they’re looking to launch clinical studies in the coming years. 

We’ve seen clients order dozens of linguistically validated COAs in 50-70 languages that they know they’ll use for upcoming trials. RWS can offer bulk discounts, maximizing efficiencies in the translation process while still adhering to ISPOR/FDA/EMA guidelines. Having paper COA translations completed well in advance of submission deadlines creates huge time savings, and creates less stress for busy study teams.

The cognitive debriefing process is the part of creating linguistically validated translations that takes the most time and has the highest cost, since patients with the trial’s disease state must be recruited in each country to test the translation’s content. By bundling patient recruitment and interviewer costs and debriefing several COAs at once, RWS is able to save pharmaceutical clients time and money without sacrificing quality.

Benefits

  • 12-14 weeks of time saved on future projects (a time savings of ~40-60% depending on the project scope!).
  • No rush fees – translations can be completed on Standard timelines since they’re ordered well in advance.
  • The ability to complete future eCOA work in ~6 weeks rather than 10 weeks, depending on the eCOA vendor’s processes.
  • Maximum reuse of paper COA translations for future studies.
  • A sponsor-owned COA translation library that grows over time.

Advance planning for paper = benefits for the electronic administration of COAs too

Proactively linguistically validating paper scales means no more waiting 60+ business days for paper + eCOA translations. Once an eCOA vendor is ready to launch their work for the pharmaceutical sponsor, RWS can get started right away on the eCOA tasks with the eCOA vendor of the sponsor’s choosing, instead of having to wait for paper translations to be completed. RWS is able to deliver a quality eCOA product on a faster timeline without needing to charge rush.

Contact RWS about this proactive approach

Want to learn more about how RWS can help you stay ahead of your submission timelines and build up a paper COA reuse library? Contact us here.
Dan Herron
Author

Dan Herron

Vice President of Digital Health at RWS
Dan Herron plays a pivotal role in leading the company's dynamic go-to-market organization. With a keen focus on strategic initiatives and cultivating robust customer relationships, Dan spearheads efforts to bring innovative technology solutions to the forefront, ultimately benefiting patients worldwide. Dan's passion for advancements in digital health drives RWS towards excellence and forward-thinking solutions in the industry.
All from Dan Herron